Pertuzumab for the treatment of HER2-positive breast cancer:a rapid health technology assessment
Objective To perform a rapid health technology assessment(rHTA)on the safety,effectiveness,and economy of pertuzumab in human epidermal growth factor receptor(HER)2-positive breast cancer,and to provide an evidence-based basis for clinical drug decision.Methods Pubmed,Cochrane Library,Embase,CNKI,Wanfang,official HTA websites were systematically searched.References were screened according to the inclusion and exclusion criterion.And the results were analyzed by data extraction and quality evaluation.Results 20 systematic review/meta-analysis,12 economic studies and 4 HTA were included in our study.The results of the study showed that in terms of effectiveness,pertuzumab can improve the pathologic conplete remission(pCR)and objective remission rate(ORR)of trastuzumab,pCR and disease free survival(DFS)of trastuzumab plus chemotherapy for neoadjuvant breast cancer patients.For the patients with metastatic breast cancer,pertuzumab can improve the progression-free survival(PFS)of trastuzumab,PFS,ORR,1-year,2-year and median overall survival(OS)of trastuzumab plus taxol,the OS of trastuzumab plus capecitabine.In terms of safety,pertuzumab had mild side effects and good safety.In terms of economy,the combination of pertuzumab was not economical both in abroad and at home.Conclusion Pertuzumab was effective and safe in the treatment of HER2-positive breast cancer,but the economy was poor.
pertuzumabhuman epidermal growth factor receptor 2-positive breast cancerrapid health technology assessmenteffectivenesssafetyeconomy